Sarms and method of use thereof
US-2016158185-A1 · Jun 9, 2016 · US
SARMs and method of use thereof
US10300037B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10300037-B2 |
| Application number | US-201715786811-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 18, 2017 |
| Priority date | Aug 24, 2006 |
| Publication date | May 28, 2019 |
| Grant date | May 28, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention is directed to substituted acylanilide compounds and uses thereof in treating muscular dystrophies such as Duchenne muscular dystrophy and Becker muscular dystrophy and in improving or preserving lung function and cardiac function in a subject suffering from Duchenne muscular dystrophy.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing the pathogenesis of myotonic dystrophy, limb-girdle muscular dystrophy, facioscapulhumeral muscular dystrophy, congenital muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, or Emery-Dreifuss muscular dystrophy in a subject in need thereof, consisting essentially of the step of administering to said subject a selective androgen receptor modulator (SARM) compound represented by the structure of formula S-XXIII: or its optical isomer, pharmaceutically acceptable salt, or any combination thereof. 2. The method of claim 1 , wherein said administering comprises administering a pharmaceutical composition comprising said compound and/or its optical isomer, pharmaceutically acceptable salt, or any combination thereof; and a pharmaceutically acceptable carrier. 3. The method of claim 1 , wherein said method further increases the physical function of said subject. 4. The method of claim 1 , wherein said method further increases the quality of life of said subject. 5. The method of claim 1 , wherein said method further delays onset or improves symptoms of cardiomyopathy and respiratory function.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- A61K31/277Primary
having a ring, e.g. verapamil · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10300037B2 cover?
- This invention is directed to substituted acylanilide compounds and uses thereof in treating muscular dystrophies such as Duchenne muscular dystrophy and Becker muscular dystrophy and in improving or preserving lung function and cardiac function in a subject suffering from Duchenne muscular dystrophy.
- Who is the assignee on this patent?
- Univ Tennessee Res Found
- What technology area does this patent fall under?
- Primary CPC classification A61K31/277. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).